The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Subscribe To Our Newsletter & Stay Updated
